HONG
KONG, Sept. 15, 2024 /PRNewswire/ -- At the
2024 European Society for Medical Oncology (ESMO) Conference, Akeso
(9926.HK) presented efficacy data for the first time for its
internally developed PD-1/VEGF bispecific antibody, ivonescimab,
with or without ligufalimab (anti-CD47 antibody AK117) , in
combination with FOLFOXIRI as a first-line (1L) treatment for
metastatic colorectal cancer (mCRC). The principal investigator of
the study, Professor Yanhong Deng
from the Sixth Affiliated Hospital of Sun Yat-Sen University,
delivered an oral presentation at the conference.
Microsatellite stable (MSS) and mismatch repair proficient
(pMMR) metastatic colorectal cancer (mCRC) tumors have long been
considered "immunological deserts," with prior attempts at
immunotherapy offering minimal benefits. The current standard
first-line treatment for MSS/pMMR mCRC patients remains a
combination of chemotherapy with bevacizumab or cetuximab, which
has shown limited therapeutic efficacy.
As of February 29, 2024, the
median follow-up time for the ivonescimab plus ligufalimab
combination with FOLFOXIRI group was 9.6 months, and 9.0 months for
the ivonescimab plus FOLFOXIRI group. Results indicated that both
regimens demonstrate high anti-tumor activity and effective disease
control for first-line treatment of MSS/pMMR mCRC, with promising
preliminary long-term outcomes. Notably, the combination of
ivonescimab with ligufalimab showed superior anti-tumor efficacy,
with preliminary data from both groups significantly surpassing
existing standard treatments.
- For first-line treatment of MSS/pMMR mCRC with ivonescimab,
either alone or in combination with ligufalimab and FOLFOXIRI, the
objective response rate (ORR) was 88.2%, and the disease control
rate (DCR) was 100%. At a median follow-up of 9.6 months, the
median progression-free survival (mPFS) has not yet been reached,
with a 9-month PFS rate of 86.2%.
- In the first-line treatment of MSS/pMMR mCRC with ivonescimab
combined with FOLFOXIRI, the ORR was 81.8% and the DCR was 100%. At
a median follow-up of 9 months, the median PFS has not yet been
reached, with a 9-month PFS rate of 81.4%.
- Both groups demonstrated acceptable safety profiles, with
manageable treatment-related adverse events (TRAEs).
- The study results support further evaluation of ivonescimab,
either alone or in combination with ligufalimab, with chemotherapy
for first-line treatment of MSS/pMMR mCRC.
View original
content:https://www.prnewswire.com/news-releases/akeso-published-first-ever-efficacy-data-for-pd-1vegf-bispecific-antibody-ivonescimab-with-or-without-cd47-antibody-plus-folfoxiri-for-mcrc-at-esmo-2024-302248431.html
SOURCE Akeso, Inc.
